Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Feature|Articles|June 1, 2026
Pharmacist’s Role in Modern Menopause Care Beyond Black Box Warnings
Author(s)Ashley Gallagher, MA
Pharmacists help women choose safer hormone replacement therapy or nonhormonal relief options.
Advertisement
Advertisement
For decades, the pharmacy counter has been a site of hesitation for women seeking relief from menopausal symptoms, often due to the stark safety warnings that once dominated the packaging of hormone replacement therapy (HRT). This landscape changed fundamentally when the FDA officially approved significant labeling updates for 6 menopausal hormone therapy products, removing risk statements regarding cardiovascular disease, breast cancer, and probable dementia from the black box warning.1,2
Related to this article
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Pharmacist Stephanie Young Moss explains menopause symptoms, hormone therapy guidance, and how pharmacists can expand menopause care access.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Advertisement
Advertisement